GHK-Cu is a copper-carrying peptide involved in collagen production and tissue remodeling. Topical products are used for skin appearance and wound care.
What GHK-Cu does and why that matters
GHK-Cu is a small copper-carrying peptide studied for signals involved in collagen production and tissue remodeling. In practical terms, topical products are intended to improve the appearance of wrinkles or support wound healing by changing how skin cells rebuild their surrounding structure. Results depend on the exact topical formulation and clinical setting. They do not show that injecting GHK-Cu improves skin, hair growth or scars throughout the body. [1,3,4,5,6,7]
Function evidence: Topical, cell and wound-care research; injection benefits unproven
What the different product claims mean
For a topical product, the hoped-for result is visible: smoother-looking skin, less noticeable wrinkles or better healing in a defined wound-care setting. Small studies have produced mixed formulation-specific findings, including one wrinkle study and a diabetic-ulcer trial, while a post-laser study found no significant improvement in its objective skin assessments. None of those studies tested whole-body injections. They cannot show that an injected product improves hair growth, fades scars everywhere or reproduces the effect of a particular cream or gel. [1,3,4,5,6,7]
What supports this description: Small formulation-specific topical studies; injection claims unsupported
GHK-Cu Dosing status
Dose: No routine injection dose established by the cited evidence. | Frequency: No validated routine injection schedule. | Cycle: No validated injection cycle. | Route: The cited human skin trials tested topical products.
Preparation: No validated patient preparation instructions in these sources..
The topical trials do not establish injectable dosing, dilution, shelf life or combined topical/injection use. FDA identifies limited human safety data for injectable GHK-Cu. [3,4,5,6]
GHK-Cu Effects
Laboratory collagen research. GHK-Cu increased collagen synthesis in fibroblast cultures. A separate culture study found increased MMP-2 expression and TIMP secretion. These are cell findings, not measured improvements in patients. [1,2]
Topical wrinkle study. A small, industry-funded eight-week study reported improved wrinkle measurements with one GHK-Cu formulation. Of 40 women enrolled, 39 completed it. The tested product and study design limit generalization to other serums or injections. [3]
Post-laser skin care. In a randomized study with 13 completers, adding topical GHK-Cu did not significantly improve objective redness, wrinkle or overall skin-quality assessments. Patient-reported skin quality favored GHK-Cu. [4]
Diabetic-ulcer research. A randomized trial reported better ulcer healing with a topical GHK-Cu gel alongside debridement and pressure-relieving footwear. This specialized wound-care setting does not establish cosmetic scar or injection benefits. [5]
GHK-Cu Side Effects
Topical tolerability. One participant in the wrinkle study stopped after a minor skin reaction to both the GHK-Cu product and its active comparator. This small study cannot establish long-term safety or an adverse-event rate for all formulations. [3]
Injectable safety uncertainty. FDA flags potential immune-response risks associated with aggregation and peptide-related impurities. Reliable side-effect frequencies for routine injections are not established by the cited sources. [6]
Frequently Asked Questions About GHK-Cu
What does the human evidence show?
It concerns specific topical formulations. A small wrinkle study reported benefit; a post-laser trial found no significant objective benefit but better patient-reported skin quality. A diabetic-ulcer trial involved specialist wound care. These are different uses, not proof that every GHK-Cu product works. [3,4,5]
Are injections more effective than a serum?
The cited human studies did not compare topical GHK-Cu with injections. They do not establish that injections improve whole-body skin, internal scars or hair growth. [3,4,5]
Is there a proven dose or serum concentration?
These sources do not establish a routine injection dose or a universal effective concentration for cosmetic serums. Results from one tested formulation cannot specify how a different product should be used. [3,4,5,6]
Is GHK-Cu safe to inject?
Safety is not established by the topical studies. FDA identifies potential immune-response risks from peptide aggregation and impurities in compounded injectable GHK-Cu, with limited human safety data. [6]
Is a cosmetic ingredient FDA-approved?
Cosmetics and their ingredients generally do not need FDA premarket approval, except for certain color additives. Being sold as a cosmetic is not evidence of FDA approval for treating disease or for injection. [7]
Evidence
Limited topical human studies; injection benefits unestablished. Human topical studies report mixed, context-specific findings. Laboratory collagen results do not establish the benefits of injections. FDA identifies limited human safety data for injectable GHK-Cu. [1,3,4,5,6]
Approval status: Cosmetic use is not FDA approval. FDA separately flags injectable compounding risks. [6,7]
References
Maquart FX, Pickart L, Laurent M, et al. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters, 1988. PMID 3169264
Siméon A, Emonard H, Hornebeck W, Maquart FX. The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sciences, 2000. PMID 11045606
Badenhorst T, Svirskis D, Merrilees M, Bolke L, Wu Z. Effects of GHK-Cu on MMP and TIMP Expression, Collagen and Elastin Production, and Facial Wrinkle Parameters. Journal of Aging Science, 2016. Source
Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Archives of Facial Plastic Surgery, 2006. PMID 16847171
Mulder GD, Patt LM, Sanders L, et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-L-histidyl-L-lysine copper. Wound Repair and Regeneration, 1994. PMID 17147644
U.S. Food and Drug Administration Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks , . Source
U.S. Food and Drug Administration FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated , . Source
Storage
Educational evidence summary. Approval applies only to the named product and indication; compounded, investigational, and research-market products are different categories.
◇An FDA-approved label or a patient-specific prescription from a licensed pharmacy
◇The active ingredient, strength, dosage form, concentration, lot, and dispensing instructions
◇Identity or purity tests only support the tests performed; they do not prove sterility, endotoxin safety, dose accuracy, stability, or clinical suitability
◇A “research use only” vial is not a patient medicine
